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Background: Inflammation and the excess production of reactive oxygen species (ROS) contribute significantly to
the pathogenesis of ischemic retinopathies such as diabetic retinopathy and retinopathy of prematurity. We
hypothesized that GKT137831, a dual inhibitor of NADPH oxidases (NOX) 1 and NOX4, reduces inflammation in the
ischemic retina by dampening the pro-inflammatory phenotype of retinal immune cells as well as macroglial Müller
cells and neurons.
Methods: Ischemic retinopathy was induced in Sprague-Dawley rats by exposure to 80 % O2 cycled with
21 % O2 for 3 h per day from postnatal day (P) 0 to P11, followed by room air (P12 to P18). GKT137831 was
administered P12 to P18 (60 mg/kg, subcutaneous) and comparisons were to room air controls. Retinal
inflammation was examined by measuring leukocyte adherence to the retinal vasculature, ionized calcium-binding
adaptor protein-1-positive microglia/macrophages, and the mRNA and protein levels of key inflammatory factors
involved in retinal disease. Damage to Müller cells was evaluated by quantitating glial fibrillary acidic protein-positive
cells and vascular leakage with an albumin ELISA. To verify the anti-inflammatory actions of GKT137831 on glia and
neurons involved in ischemic retinopathy, primary cultures of rat retinal microglia, Müller cells, and ganglion cells
were exposed to the in vitro counterpart of ischemia, hypoxia (0.5 %), and treated with GKT137831 for up to 72 h.
ROS levels were evaluated with dihydroethidium and the protein and gene expression of inflammatory factors with
quantitative PCR, ELISA, and a protein cytokine array.
Results: In the ischemic retina, GKT137831 reduced the increased leukocyte adherence to the vasculature, the
pro-inflammatory phenotype of microglia and macroglia, the increased gene and protein expression of vascular
endothelial growth factor, monocyte chemoattractant protein-1, and leukocyte adhesion molecules as well as
vascular leakage. In all cultured cell types, GKT137831 reduced the hypoxia-induced increase in ROS levels and
protein expression of various inflammatory mediators.
Conclusions: NOX1/4 enzyme inhibition with GKT137831 has potent anti-inflammatory effects in the retina,
indicating its potential as a treatment for a variety of vision-threatening retinopathies.
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Ischemic retinopathies such as retinopathy of prematur-
ity and diabetic retinopathy are major causes of vision
loss and blindness in infants and people of working age,
respectively [1, 2]. Current treatments such as laser
photocoagulation are used to reduce the severe micro-
vascular and tissue damage that occur in the end stages
of these diseases. However, although these treatments
are somewhat successful, they do not prevent the ad-
vancement of retinopathy from its early to late stages.
New strategies that target the underlying mechanisms
involved in the development of ischemic retinopathies
are of considerable interest.
Inflammation has emerged as an important factor in
the vascular damage that develops in ischemic retinopa-
thies as well as other retinal diseases and involves contri-
butions from circulating leukocytes as well as a local
neuroglial inflammatory response [3, 4]. The activation
and proliferation of resident macrophages, known as
microglia, injure retinal blood vessels by their increased
production of cytokines [5, 6], and macroglial Müller
cells, which have an integral role in the maintenance of
the blood-retinal barrier, become gliotic and exhibit a pro-
inflammatory phenotype [4, 7, 8]. Moreover, ganglion cells
are injured by the increased production of cytokines from
activated microglia [9]. These glial and neuronal cell pop-
ulations are also key producers of vascular endothelial
growth factor (VEGF), a potent angiogenic and permeabil-
ity factor in the ischemic retina [7, 10], which also has
pro-inflammatory actions including the attraction of leu-
kocytes to tissues [11].
A central mechanism mediating these inflammatory
pathways is the excess production of reactive oxygen
species (ROS), which promotes the stabilization of the
transcription factor, hypoxic inducible factor-1α, to in-
crease the expression of VEGF and chemoattractants
such as monocyte chemoattractant protein-1 (MCP-1)
[12–14]. Tissue inflammation is exacerbated by further
increases in ROS production due to stimulation by cyto-
kines and growth factors including interleukin (IL)-6
and tumor necrosis factor-α (TNFα) [14, 15]. There is
considerable interest in the role of the nicotinamide ad-
enine dinucleotide phosphate (NADPH) oxidase enzyme
family as the source of excess ROS production in a wide
range of diseases including retinopathy [14]. Indeed, phar-
macological approaches to target NADPH oxidase have
been the subject of substantial investigation in order to
develop relevant and effective medical treatments [16].
It is now appreciated that previous approaches have
largely used agents that are non-specific for NADPH
oxidase, which may account for their failure in a clinical
setting [16].
Identification that the NADPH oxidase catalytic unit,
NOX, exists in seven isoforms (NOX1 to 5, DUOX1,DUOX2) has led to significant research to determine the
role of individual NOX isoforms in a variety of diseases
and whether their inhibition has therapeutic potential
[16–20]. NOX1, 2, and 4 are implicated in the pathogen-
esis of ischemic retinopathies [21–24], and phagocytic
NOX2 contributes to retinal inflammation [23, 25].
However, due to NOX2’s key role in defense against
pathogens, complete blockade of NOX2 may not be en-
tirely suitable as a treatment approach in humans [16, 26].
Interestingly, emerging evidence indicates that NOX1
and NOX4 have pro-inflammatory actions [19, 27, 28].
GKT137831, a member of the pyrazolopyridine dione
family, is a small molecule that potently inhibits NOX1
and NOX4 (Ki in the range of 100–150 nM in cell-free
assays of ROS production using membranes prepared
from cells heterologously overexpressing specific NOX
enzyme isoforms) [29]. The therapeutic potential of
GKT137831 has been demonstrated in various animal
models of disease [19, 29–32] and is currently being eval-
uated in the clinic [16]. However, whether the benefits of
GKT137831 extend to the extensive retinal inflammation
that develops in ischemic retinopathies has not been ex-
plored. Here, using a rat model of retinopathy of prema-
turity, known as oxygen-induced retinopathy (OIR), and
in vitro cultures of retinal cells, we show that GKT137831
attenuates the ischemia/hypoxia-induced pro-inflammatory




GKT137831 (Genkyotex SA, Geneva, Switzerland) is an
efficient inhibitor of both NOX1 and NOX4 isoforms
(Ki 100–150 nM and Emax >90 %). GKT137831 has sub-
stantially less activity towards the NOX2 isoform in cell-
free assays (Ki 1500 nM and Emax 60–70 %) and is also a
weak inhibitor of the NOX2 isoform in cell-free assays
but does not significantly inhibit neutrophil oxidative
burst at concentrations up to 100 μM and does not in-
hibit innate microbial bacterial killing in vitro or in vivo
(when used at a concentration of up to 20 μM or admin-
istered at 100 mg/kg orally, respectively). Furthermore,
GKT137831 has no scavenging nor antioxidant activity
when tested at up to 100 μM and has an excellent speci-
ficity for NOX1 and NOX4 enzymes as shown in an ex-
tensive in vitro off-target pharmacological profiling on
which included 170 different proteins including ROS
producing and redox-sensitive enzymes [30, 31].
Animals
All procedures were approved by the Alfred Medical
Research and Education Precinct (AMREP) Animal Eth-
ics Committee (application E/1061/2011/M) and per-
formed according to the National Health and Medical
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for the Care of Animals in Scientific Research. Sprague-
Dawley rats were purchased from the Animal Resources
Centre (ARC, Perth, Western Australia).Oxygen-induced retinopathy
OIR was induced in Sprague-Dawley rats using a previ-
ously published method [33–35]. OIR develops over two
phases comprising vaso-obliteration (phase I) and neo-
vascularization (phase II). In phase I, rats were exposed
to 80 % O2 cycled with 21 % O2 for 3 h per day between
postnatal days 0 and 11. Phase II of OIR occurred when
rats were placed in room air between postnatal days 12
to 18. Controls were in room air for the entire study.
Litters were randomized to receive a subcutaneous in-
jection (100 μl) of GKT137831 (60 mg/kg/day) or ve-
hicle (25 % dimethyl sulfoxide) between P12 to P18. Rat
pups were entered into the study if they had a body
weight of approximately 8 g on postnatal day 3. The
body weight of pups was measured each day, and litter
sizes were kept to 14 pups. The dose of GKT137831 was
based on previous studies in which it effectively reduced
vascular disease [33]. Rats were killed at postnatal day
18 with sodium pentobarbitone (170 mg/ml, Virbac,
NSW, Australia).Immunohistochemistry for microglia and Müller cell
gliosis in OIR
Using an established method [33, 35], 3-μm paraffin sec-
tions were incubated overnight at 4 °C with antibodies
to ionized calcium-binding adapter molecule 1 (Iba1) to
detect microglia (1:1000, Wako, Tokyo, Japan) and glial
fibrillary acidic protein to detect gliosis (GFAP, 1:500,
DakoCytomation, Glostrup, Denmark). A negative con-
trol without the primary antibody and an isotype IgG
control was included in each experiment. Immunolabel-
ing in sections incubated with Iba1 was visualized with a
Vectastain ABC standard kit (Vector Laboratories Inc.,
CA, USA) and liquid DAB + substrate chromagen sys-
tem (DakoCytomation). Immunolabeling for GFAP was
visualized following incubation of the sections with
Alexa Fluro 488-conjugated goat anti-rabbit IgG (1:200,
Life Technologies, VIC, Australia). For quantitation, four
sections at least 60 μm apart were randomly selected
from each eye. In each section, four non-overlapping
fields spanning the entire retina were captured at ×400
magnification using a Spot digital camera (SciTech, VIC,
Australia). Image J software was used to set a threshold
for immunolabeling which was applied to all fields. For
Iba1, immunolabeling was quantitated in the inner retina
(from the retinal surface to the inner plexiform layer),
and for GFAP, all retinal layers were sampled. Five to six
rats per group were evaluated.Retinal leukostasis
Following a previously published method [33, 36], rats
were perfused via the right atrium with 0.1 M phosphate-
buffered saline, pH 7.4, to clear blood cells and then
rhodamine-conjugated Concanavalin A lectin (0.25 mg/
kg, Vector Laboratories) to stain adherent leukocytes and
the endothelium. Eyes were fixed in 4 % paraformaldehyde
in 0.1 M phosphate-buffered saline, pH 7.4, for 30 min
and retina flat-mounted. Non-overlapping images at ×200
magnification were captured, and the number of leuko-
cytes per retina were counted. Six to nine rats per group
were evaluated.
Retinal vascular leakage
Albumin levels in freshly frozen single retina were mea-
sured according to the manufacturer’s instructions using
a commercially available rat albumin ELISA quantifica-
tion set (Bethyl Laboratories, Montgomery, TX, USA) as
previously described [37]. Albumin values were normal-
ized to dry retinal weight. Six to seven rats per group
were evaluated.
Protein levels of VEGF, MCP-1, and intercellular adhesion
molecule-1 (ICAM-1) in retina
VEGF and MCP-1 were measured as described previ-
ously [37]. Briefly, supernatants from retinal lysates were
collected, and the total protein concentration was quan-
titated using the Bradford colorimetric method (Bio-Rad
Laboratories, NSW, Australia) according to the manu-
facturer’s protocol. Undiluted supernatants were then
assayed using a commercially available rat VEGF, ICAM-
1 (R&D Systems, MN, USA), and MCP-1 ELISA kits
(BD Biosciences, CA, USA). All procedures were per-
formed according to the manufacturer’s instructions. Six
rats per group were evaluated.
Real-time PCR
Total RNA was isolated using an RNeasy kit (Qiagen,
Doncaster, VIC, Australia) according to the manufac-
turer’s protocol, and then 1 μg of RNA was subjected to
DNase treatment (DNA-free kit, Ambion, Carlsbad, CA,
USA) and reverse transcription (First Strand cDNA syn-
thesis kit, Roche, Switzerland). For quantitative assess-
ment of mRNA expression, gene-specific primers and
cDNA (20 ng) were mixed with the SYBR Master Mix
(Invitrogen), and real-time PCR was conducted using an
ABI 7900 HT Sequence Detection System (Applied Bio-
systems) [34]. mRNA expression was normalized to 18s
rRNA endogenous control, and the relative fold difference
in expression was calculated using the comparative 2-ΔΔCt
method [34]. The primer sequences used in the study are
previously published [37], except for platelet endothelial
cell adhesion molecule-1 (PECAM-1), forward primer—5′
GGCCAGCAGTCCCACTTCT3′ and reverse primer—5′
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per group were evaluated.
Primary culture of rat retinal microglia and Müller cells
Primary cultures were performed as previously published
[33, 35, 37]. Briefly, retinas were collected from 4- to 6-
day-old Sprague-Dawley rats, digested, suspended in cul-
ture medium (low-glucose DMEM, Gibco, NY, USA),
and cultured until reaching confluence at 10 to 12 days.
Flasks were then shaken for 3 h at 37 °C at 200 rpm to re-
move microglia. After shaking, the culture supernatant
was removed, and remaining cells were plated onto either
poly-D-lysine coated 6-well plates or coverslips. Microglia
and Müller cells were characterized as previously de-
scribed [33, 35, 37]. Cells were exposed to hypoxia (0.5 %
O2, 94.5 % N2, and 5 % CO2) in a modular incubator
chamber (MIC101; QNA International Pty Ltd, VIC,
Australia) for 4, 8, 16, or 72 h. Comparisons were made to
cells exposed to normoxia. Experiments were repeated
three to four times with at least three replicates per
experiment.
Primary culture of rat retinal ganglion cells
Primary cultures were performed as previously described
with some minor modifications [35, 38]. Retinas were col-
lected from 3-day-old Sprague-Dawley rats and digested
for 10 min at 37 °C in Hanks balanced salt solution
(HBSS, no Ca2+/Mg2+, Gibco) with 0.2 g/L trypsin and 80
U/ml DNase I. Digestion was quenched by the addition of
0.5 mg/ml soybean trypsin inhibitor (Gibco) in HBSS and
suspended in HBSS with 0.2 % bovine serum albumin
(Sigma, MO, USA). The cell suspension was passed
through a 40-μM nylon mesh (BD Biosciences, CA, USA)
and transferred to the negative panning plate coated with
BS-1 lectin (10 μg/ml, Sigma) and incubated for 30 min at
room temperature to remove microglia. Cells were then
transferred to the positive panning plate coated with a
goat anti-mouse IgM (10 μg/ml, chain specific, Jackson
ImmunoResearch, PA, USA) a mouse anti-rat Thy1.1 anti-
body (10 μg/ml, clone T11D7e, Serotec, Oxford, UK) and
incubated for 45 min at room temperature. Non-adherent
cells were washed thoroughly with HBSS. Bound cells
were collected by trypsination (0.25 %, Gibco). Ganglion
cells were plated onto poly-D-lysine (10 μg/ml, Sigma)
and laminin (50 μg/ml, Sigma) coated coverslips or
24-well plates in retinal ganglion cell culture media
(Neurobasal media A [Invitrogen, Carlsbad, CA, USA],
1× B27 supplement [Gibco], 2 mM glutamine, 10 % dia-
lyzed FBS [Gibco], 100 μM forskolin, 25 ng/ml ciliary
neurotrophic factor, 10 ng/ml brain-derived neurotrophic
factor, and 1× penicillin-streptomycin solution [Sigma]).
Experiments were conducted 7 days after isolation. Char-
acterization of retinal ganglion cells was as previously
described [35]. GKT137831 was dissolved in vehicle(0.0001 % dimethyl sulfoxide). Ganglion cells were ex-
posed to hypoxia (0.5 % O2, 94.5 % N2, and 5 % CO2) in a
modular incubator chamber for 4 and 16 h. Comparisons
were made to cells exposed to normoxia. Experiments
were repeated three to four times with three replicates per
experiment.ROS levels in rat retinal microglia, Müller cells, and
ganglion cells
The levels of ROS were measured as previously reported
[33]. Primary cultured cells were washed with HBSS for
2 min followed by a 30-min incubation with 5 μM dihy-
droethidium at 37 °C in 5 % CO2 in the dark. After incu-
bation, cells were washed with HBSS and then imaged
immediately using an Eclipse TE2000 inverted fluores-
cence microscope (Nikon Instruments Inc., Melville, NY,
USA) and image processing computer software (NIS-
Elements version 2.20, Nikon Instruments Inc.). The
fluorescence intensity of cells was used as a measure of
intracellular ROS levels using Image J analytical software
(version 1.44, Bethesda, MD, USA). For quantitation, a
minimum of 15 randomly selected cells from three differ-
ent fields from each dish was evaluated. The intensity of
fluorescence in a blank space between two cells was mea-
sured as background intensity. Three to four independent
experiments were performed in each group with a mini-
mum of three replicates.Protein levels of inflammatory mediators in cultured
retinal cells
The protein levels of cytokines in supernatant of cultured
rat microglia were measured using a rat cytokine antibody
array performed according to the manufacturer’s instruc-
tions (R&D Systems Inc., Australia). The protein levels of
MCP-1, VEGF, and soluble ICAM-1 (BD Biosciences, San
Jose, CA, USA) as well as IL-6 (R&D Systems Inc.) were
measured in supernatant of cultured rat Müller cells, and
VEGF was measured in cultured rat ganglion cells using
commercially available ELISA kits.Statistics
All data were analyzed using the GraphPad Prism Soft-
ware (v.5, San Diego, California, USA). Normality was
assessed by the Pearson, Shapiro-Wilk, and Kolmogoro-
Smirnov normality tests. Analyses were performed by
using a one-way ANOVA followed by appropriate post
hoc analysis correcting for the number of comparisons
and unpaired t tests (parametric) or a Kruskal-Wallis test
followed by Mann-Whitney U tests (non-parametric). In-
vestigators were masked to the groups. A value of P < 0.05
was considered significant.
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GKT137831 reduced Iba1-positive microglia and
leukostasis in OIR
OIR is associated with increased microglial cell density in
the retina compared to room air controls, which can be
demonstrated by immunolabeling for Iba1 [33, 37]. This
occurred in the present study with microglia in OIR con-
trol rats often localized to blood vessels protruding into
the vitreous cavity (Fig. 1a to d). In OIR rats, GKT137831
reduced Iba1 immunolabeling to the level of room air
controls (Fig. 1a to d). As the adherence of leukocytes to
the retinal vasculature contributes to the development of
ischemic retinopathy [11], we evaluated retinal leukostasis
in rats with OIR. In OIR controls, retinal leukostasis was
increased compared to room air controls. In OIR rats,
GKT137831 reduced retinal leukostasis (Fig. 1e to h).GKT137831 reduced the expression of pro-inflammatory
mediators in OIR
As the upregulation of pro-inflammatory mediators is a
feature of OIR, these factors were measured in the retinaFig. 1 In OIR, GKT137831 reduced Iba1 immunolabeling of microglia and le
of retina immunolabeled with ionized calcium-binding adapter molecule 1
compared to room air controls, and in OIR controls, it is present in pre-reti
treatment with GKT reduced Iba1 immunolabeling. Scale bar = 40 μm. GCL
d Iba1 immunolabeling was quantitated in the inner retina (from retinal su
mounts of retina from rats perfused with Concanavalin A to show leukocyt
increased in OIR controls compared to room air controls. In OIR, treatment
quantitated in the entire retina. n = 6 to 9 rats per group. **P < 0.01 to roo[33, 37]. OIR resulted in increased mRNA and protein
levels of VEGF, MCP-1, and ICAM-1, as well as mRNA
levels of vascular cellular adhesion molecule-1 (VCAM-1)
and PECAM-1 compared to room air controls (Fig. 2a to h).
In OIR rats, GKT137831 reduced all inflammatory factors
(Fig. 2a to h).GKT137831 reduced retinal gliosis and vascular leakage
in OIR
Retinal gliosis can be robustly measured with immunola-
beling for GFAP [4]. In room air controls, GFAP immu-
nolabeling was restricted to the retinal surface (Fig. 3a),
whilst in OIR controls, GFAP immunolabeling was
present in Müller cell processes extending the width of
the retina (Fig. 3b). In OIR rats, GKT137831 reduced
GFAP labeling (Fig. 3c and d). As Müller cell gliosis is
associated with disruption of the blood-retinal barrier
[4], vascular leakage was measured. In OIR controls, vas-
cular leakage was increased compared to controls. In OIR
rats treated with GKT137831, vascular leakage was re-
duced compared to OIR controls (Fig. 3e).ukostasis. GKT137831 (GKT). a–c Representative 3-μm paraffin sections
(Iba1, arrowheads). Iba1 immunolabeling is increased in OIR controls
nal blood vessels (asterisk) protruding into the vitreous cavity. In OIR,
ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer.
rface to IPL). n = 5 to 6 rats per group. e–g Representative whole
es (arrowheads) adherent to the retinal vasculature. Leukostasis is
with GKT reduced leukostasis. Scale bar = 40 μm. h Leukostasis was
m air control. ##P < 0.01 to OIR control. Values are mean ± SEM
Fig. 2 (See legend on next page.)
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Fig. 2 In OIR, GKT137831 reduced inflammatory mediators in the retina. GKT137831 (GKT). mRNA levels were determined in the whole retina by
quantitative PCR. Protein levels in the whole retina were measured by ELISA. a, b VEGF mRNA and protein. c, d MCP-1 mRNA and protein.
e, f ICAM-1 mRNA and protein. g VCAM-1 mRNA. h PECAM-1 mRNA. *P < 0.05, **P < 0.01, and ***P < 0.001 to room air control. #P < 0.05, ##P <
0.01, and ###P < 0.001 to OIR control. n = 9 to 10 rats per group. Values are mean ± SEM
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inflammatory mediators in retinal microglia exposed to
hypoxia
As microglia are the principal resident inflammatory
cells in the retina, we examined ROS levels and the
expression of a various inflammatory mediators impli-
cated in ischemic retinopathy. Exposure of microglia to
hypoxia for 4 h resulted in increased mRNA levels of
NOX1, NOX2, and NOX4, and by 16 h, NOX1 and
NOX4 mRNA levels remained elevated (Table 1). Sub-
sequent experiments were performed at 16 h to allow
for maximal increases in protein expression. After 16 h
of hypoxia, ROS levels were increased compared to
normoxia controls (Fig. 4a and b). In addition, proteinFig. 3 In OIR, GKT137831 reduced Müller cell gliosis and vascular leakage in
retina immunolabeled with glial fibrillary acidic protein (GFAP). GCL ganglio
controls, GFAP immunolabeling is detected at the retinal surface (asterisk),
retina in Müller cell processes (arrowheads). In OIR rats treated with GKT137
bar = 40 μm. d GFAP immunolabeling was quantitated in the entire retina
retina by an albumin ELISA. n = 6 to 7 rats per group. *P < 0.05, **P < 0.01
are mean ± SEMlevels of VEGF, IL-6, TNFα, IL-1β, ICAM-1, CINC2,
CINC3, RANTES (regulated on activation, normal T
cell expressed and secreted), CXCL3, CXCL5, inter-
feron ϒ (IFNϒ), and MCP-1 were increased by hypoxia
compared to normoxia controls (Fig. 4c to n). The
hypoxia-induced increase in ROS and inflammatory
mediators was reduced with GKT137831 (Fig. 4a to n).
GKT137831 reduced ROS levels and the expression of
inflammatory mediators in retinal Müller cells exposed to
hypoxia
As macroglial Müller cells play an important role in retinal
homeostasis [4], we examined ROS levels and the expres-
sion of inflammatory mediators known to be upregulatedretina. GKT137831 (GKT). a–c Representative 3-μm paraffin sections of
n cell layer, INL inner nuclear layer, ONL outer nuclear layer. In room air
whilst in OIR controls, GFAP immunolabeling extends throughout the
831, GFAP immunolabeling is reduced compared to OIR controls. Scale
. n = 5 to 6 rats per group. e Vascular leakage was measured in single
, and ***P < 0.001 to room air control. ##P < 0.01 to OIR control. Values
Table 1 mRNA levels of NOX1, NOX2, and NOX4 in primary cultures of rat retinal microglia, Müller cells, and ganglion cells exposed
to normoxia and hypoxia
Microglia Müller cells Ganglion cells
4 h 16 h 8 h 72 h 8 h 16 h
NOX1
N 1.01 ± 0.01 1.01 ± 0.00 1.00 ± 0.00 1.00 ± 0.01 1.00 ± 0.00 1.00 ± 0.00
H 1.31 ± 0.06** 3.06 ± 0.28** 0.90 ± 0.13 1.63 ± 0.11** 2.90 ± 0.25* 2.45 ± 0.47*
NOX2
N 1.00 ± 0.00 1.02 ± 0.02 1.04 ± 0.04 1.01 ± 0.01 1.02 ± 0.01 1.06 ± 0.04
H 2.15 ± 0.21** 0.93 ± 0.07 0.87 ± 0.11 1.16 ± 0.18 1.26 ± 0.52 1.12 ± 0.21
NOX4
N 1.01 ± 0.01 1.01 ± 0.01 1.00 ± 0.00 1.00 ± 0.01 1.03 ± 0.02 1.01 ± 0.00
H 1.66 ± 0.11*** 1.77 ± 0.04*** 0.96 ± 0.04 0.70 ± 0.14 1.02 ± 0.10 1.01 ± 0.12
Values are mean ± SEM. n = 3 to 4 independent experiments and performed in triplicate
N normoxia (21 % O2), H hypoxia (0.5 % O2)
*P < 0.05, **P < 0.01, and ***P < 0.001 to normoxia control
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Müller cells to hypoxia for 8 and 72 h resulted in elevated
levels of NOX1 mRNA but not NOX2 mRNA and NOX4
mRNA (Table 1). Subsequent experiments were performed
at 72 h, and hypoxia resulted in elevated ROS levels
compared to normoxia controls (Fig. 5a and b). Hypoxia
increased the protein levels of VEGF, IL-6, soluble ICAM-1,
and MCP-1 compared to normoxia controls (Fig. 5c to f).
The hypoxia-induced increase in ROS and inflammatory
mediators was reduced with GKT137831 (Fig. 5a to f).
GKT137831 reduced ROS levels and the expression of
VEGF in retinal ganglion cells exposed to hypoxia
Exposure of ganglion cells to hypoxia for 4 and 16 h
resulted in elevated levels of NOX1 mRNA, but not
NOX2 mRNA and NOX4 mRNA levels (Table 1). Subse-
quent experiments were performed at 16 h, and ROS
levels and VEGF protein levels were increased by hyp-
oxia compared to normoxia controls (Fig. 6a and c). The
hypoxia-induced increase in ROS and VEGF were re-
duced with GKT137831 (Fig. 6c).
Discussion
The chronic production of excessive ROS is central
to the development of inflammatory diseases including
those of the retina [14, 41]. Emerging evidence indicates
ROS derived from NOX1, and NOX4 contributes to
tissue inflammation [27, 28], and hence the development
of specific inhibitors targeting these NOX isoforms is
likely to have therapeutic potential for various inflamma-
tory diseases. We previously reported dual NOX1/4 in-
hibition with GKT137831 reduced the OIR-induced
increase in ROS levels and neovascularization in the ret-
ina [33]. The present study demonstrates for the first
time that GKT137831 administered at the onset of tissueischemia in phase II of OIR has marked anti-inflammatory
actions, evidenced by a reduction in the adherence of cir-
culating leukocytes to the retinal vasculature and the pro-
inflammatory phenotype of retinal microglia, macroglial
cells, and ganglion cells. Our in vitro studies, designed to
resemble phase II of OIR, show that at the time points
studied, hypoxia induced the upregulation of NOX1 and/
or NOX4, and GKT137831 has direct anti-inflammatory
actions on neuroglial cell populations.
Increased leukocyte adherence to the retinal vasculature
is a feature of ischemic retinopathies [11, 42]. Indeed,
the expression of leukocyte adhesion molecules such
as ICAM-1 and VCAM-1 are increased in models of OIR
[42, 43], and chemoattractants such as RANTES are
elevated in the vitreous fluid of children with retinopathy
of prematurity [44]. Consistent with the notion of sys-
temic inflammation contributing to OIR are findings that
vitreal macrophages are attracted to, and participate in,
retinal neovascularization [45]. The ability of GKT137831
to reduce retinal leukostasis in OIR as well as the expres-
sion of MCP-1, ICAM-1, VCAM-1, and PECAM-1 in the
retina suggests that GKT137831 interrupts leukocyte
adherence to the retinal vasculature. This idea is in agree-
ment with evidence that NOX1 is involved in the cytokine-
induced adhesion of monocytes to vascular smooth muscle
cells [46].
The involvement of microglia in retinal inflammation
is complex as this cell type transitions from a protective,
ramified, and M2 phenotype to an activated and amoeboid-
shaped cell with M1 properties [47]. In an activated state
due to hypoxia or other stressors, microglia are a major
source of chemokines, adhesion molecules, and cytokines
as well as growth factors, which have detrimental effects
on various cell types in the retina [6]. Systemic inflamma-
tion may contribute with evidence that lipopolysaccharide
Fig. 4 In cultured microglia, elevated ROS and protein levels of inflammatory mediators were reduced with GKT137831. N normoxia control (21 %
O2), H hypoxia control (0.5 % O2). GKT137831 (GKT), 5 μM. Primary cultures of rat retinal microglia exposed to normoxia, hypoxia, and GKT for 16
h. a Quantitation of ROS levels. b Micrographs of retinal microglia labeled with dihydroethidium to detect ROS. Scale bar = 100 μm. c–n Protein
levels of inflammatory mediators were measured by a rat cytokine antibody array. c VEGF. d IL-6. e TNFα. f IL-1β. g Soluble ICAM-1 (sICAM-1).
h CINC2. i CINC3. j RANTES. k CXCL3. l CXCL5. m IFNϒ. n MCP-1. *P < 0.05, **P < 0.01, and ***P < 0.001 to normoxia control. #P < 0.05 and
##P < 0.01 to hypoxia control. Values are mean ± SEM. n = 3 to 4 independent experiments and performed in triplicate
Deliyanti and Wilkinson-Berka Journal of Neuroinflammation  (2015) 12:136 Page 9 of 13administration to mice resulted in the activation of retinal
microglia [48]. In the present study, GKT137831’s reduc-
tion of Iba1-positive microglia in OIR suggested aprotective effect on this cell population due to inhibition
of ROS derived from NOX1/4. However, it is recognized
that Iba1 also labels macrophages, and hence, this cell type
Fig. 5 In cultured Müller cells, elevated ROS and protein levels of inflammatory mediators were reduced with GKT137831. N normoxia control
(21 % O2), H hypoxia control (0.5 % O2). GKT137831 (GKT), 5 μM. Primary cultures of rat retinal Müller cells exposed to normoxia, hypoxia, and GKT
for 72 h. a Quantitation of ROS levels. b Micrographs of retinal Müller cells labeled with dihydroethidium to detect ROS. Scale bar = 100 μm.
c–f Protein levels measured by ELISA. c VEGF. d IL-6. e Soluble ICAM-1 (sICAM-1). f MCP-1. *P < 0.05, **P < 0.01, and ***P < 0.001 to normoxia
control. #P < 0.05, ##P < 0.01, and ###P < 0.001 to hypoxia control. Values are mean ± SEM. n = 3 to 4 independent experiments and performed
in triplicate
Fig. 6 In cultured retinal ganglion cells, elevated ROS and VEGF protein levels were reduced with GKT137831. N normoxia control (21 % O2),
H hypoxia control (0.5 % O2). GKT137831 (GKT), 5 nM. Primary cultures of rat retinal ganglion cells exposed to normoxia, hypoxia, and GKT for 16
h. a Micrographs of retinal ganglion cells labeled with dihydroethidium to detect ROS. Scale bar = 100 μm. b Quantitation of ROS levels. c VEGF
protein levels measured by ELISA. **P < 0.01 and ***P < 0.001 to normoxia control. ##P < 0.01 and ###P < 0.001 to hypoxia control. Values are
mean ± SEM. n = 3 to 4 independent experiments and performed in triplicate
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glia. By utilizing primary cultures of retinal microglia ex-
posed to hypoxia to mimic the ischemia that occurs in
phase II of OIR, we were able to directly assess this cell
population and show that NOX1, NOX4, and ROS levels
are increased. The ability of GKT137831 to reduce the
hypoxia-induced increase in ROS and the inflammatory
molecules, VEGF, IL-6, and TNFα, indicates that dual
inhibition of NOX1/4 has potent anti-inflammatory ef-
fects in the key immunocompetent cell of the retina.
GKT137831’s anti-inflammatory properties extended to a
reduction in leukocyte recruitment molecules including
MCP-1, RANTES, CINC2, CINC3, CXCL3, and CXCL5
as well as ICAM-1 and VCAM-1 and emphasize the ability
of this agent to dampen the strong pro-inflammatory sig-
nals produced by activated retinal microglia. Our findings
are consistent with recent reports showing GKT137831
reduced macrophage infiltration in diabetic kidney [49] and
T cell numbers in atherosclerosis [19]. A limitation of our
study is that we did not evaluate whether inhibition of
ROS derived from NOX1/4 in retinal microglia is the
primary event conferring protection against hypoxia-
mediated damage to other glia cell populations and
neurons in the retina [9, 39]. Certainly, future studies
in this aspect of retinal inflammation are of interest.
Macroglial Müller cells have numerous functions that
are vital to retinal homeostasis including neuroprotec-
tion, suppression of inflammation, and maintenance of
the blood-retinal barrier [4]. When injured, Müller cells
exhibit a pro-inflammatory phenotype [4] reflected by
increased expression of MCP-1 and ICAM-1 [50, 51].
The health of Müller cells is robustly demonstrated by
measuring GFAP, a marker of intermediate filaments [4].
In uninjured retina, GFAP expression is restricted to as-
trocytes at the retinal surface, whilst in disease, Müller
cells exhibit GFAP along their cell processes which span
almost the entire width of the retina [4, 6, 8]. In OIR,
Müller cell gliosis and inflammation is a major contribu-
tor to breakdown of the blood-retinal barrier [4, 52].
GKT137831’s anti-inflammatory effects in Müller cells
suggest this translated to prevention of their gliosis and
vascular leakage in OIR. Our findings in cultured Müller
cells confirmed GKT137831’s anti-inflammatory proper-
ties, and the upregulation of NOX1 in response to hypoxia
suggested that this NOX isoform is likely to be involved in
ROS-mediated inflammatory effects in Müller cells.
An important finding was the ability of GKT137831 to
reduce VEGF in microglia, Müller cells, and ganglion cells.
VEGF’s potent pro-angiogenic and pro-permeability ac-
tions are well documented and form the basis of treat-
ments such as bevacizumab for diabetic retinopathy [53].
Furthermore, VEGF is a potent chemoattractant stimulat-
ing increased ICAM-1 expression and leukocyte adhesion
in the retina [11]. In a previous study, we demonstratedGKT137831 reduced retinal neovascularization in rats
and mice with OIR [33] but did not evaluate in detail the
retinal cell types in which GKT137831 modulated VEGF
expression. Our findings in the current study indicate that
GKT137831’s effects in ischemic retinopathy involve the
attenuation of amplified VEGF levels in neuroglial cell
populations. In addition, retinal ganglion cells, which
make a major contribution to VEGF production in phase
II of OIR [10], predominately express NOX1. This finding
is consistent with a previous study showing that hypoxia
and glucose deprivation induced the expression of this
NOX isoform in retinal ganglion cells [54].
Conclusions
Increasing evidence indicates that ROS derived from spe-
cific isoforms of NOX contributes to retinal disease. Here,
we describe the ability of a specific NOX1/4 inhibitor,
GKT137831, to attenuate ischemic-induced inflammation
in the retina and neuroglia. GKT137831 is currently in
clinical development, albeit for other diseases. Our find-
ings suggest that NOX1/4 inhibition may provide a new
treatment strategy for inflammatory ocular diseases, which
feature the excess production of ROS from these NOX
isoforms.
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